COVID-19 Update - This is to inform you that the Government of India has announced a complete lockdown in India 22nd March 2020 to 3rd May 2020. As a result, our offices will now be closed till 3rd May 2020 and all our employees will be working from home. Office telephones will not be answered, and therefore you are requested to direct all your queries related to manuscript submission, review process, publication etc. at below mentioned details. editor@innovativepublication.com, rakesh.its@gmail.com, Mob. 8826373757, 8826859373, 9910947804


Print ISSN:-2395-1443

Online ISSN:-2395-1451

CODEN : IJCEKF

Current Issue

Year 2020

Volume: 6 , Issue: 1

Article Access statistics

Viewed: 367

Emailed: 0

PDF Downloaded: 109

Indian Journal of Clinical and Experimental Ophthalmology


A study on the use of topical bepotastine besilate ophthalmic solution (BBOS) 1.5% in the treatment of allergic conjunctivitis


Full Text PDF Share on Facebook Share on Twitter


Research Article

Author Details : Nageshwar Sharma*, Jayshree Kedia

Volume : 5, Issue : 3, Year : 2019

Article Page : 310-313


Suggest article by email


Abstract

The study was conducted to ascertain the efficacy and safety of topical bepotastine besilate solution (BBOS) 1.5% in controlling allergic conjunctivitis. The study design was randomized and out-patient department (OPD) based. Total 50 patients were included. They had symptoms and signs of allergic conjunctivitis. Symptoms included ocular itching, conjunctival redness, watering running nose, lacrimation, photophobia and foreign body sensation and signs included papillae, follicles, chemosis, hyperaemia and cobblestones. The data was gathered together after detailed history taking. We recorded baseline symptoms score(BSS) of each patient who fulfilled the inclusion and exclusion criteria. After that we started topical BBOS 1.5% one drop twice daily for 21 days and advised patients to immediately stop the drug and review in OPD in case of any aggravation of symptoms or burning sensation.
We examined patients on each follow up day 7, day 14 and day 21 by slit lamp biomicroscopy and recorded total mean symptoms and signs. Symptoms of allergic conjunctivitis especially ocular itching subsided within 7 days of the treatment, while other significant signs and symptoms subsided within 14 days of treatment. The interesting fact was observed that on 21st day of follow up cobblestones were flattened.
To conclude the use of bepotastin besilate 1.5% topically leads to an improvement in sign and symptoms in a significant number of patients. No significant side effects were noticed and patient compliance has been encouraging.
We recommended the use of BBOS 1.5% eye drop in all patents of mild to moderate allergic conjunctivitis.

Keywords: Allergic conjunctivitis, Bepotastine besilate ophthalmic solution (BBOS), Cobblestones, Itching, Redness.

Doi : 10.18231/j.ijceo.2019.074

How to cite : Sharma N, Kedia J, A study on the use of topical bepotastine besilate ophthalmic solution (BBOS) 1.5% in the treatment of allergic conjunctivitis. Indian J Clin Exp Ophthalmol 2019;5(3):310-313

Copyright © 2019 by author(s) and Indian J Clin Exp Ophthalmol. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) (creativecommons.org)